Today: 20 May 2026
Browse Category

NASDAQ:RANI 17 October 2025 - 28 November 2025

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

Rani Therapeutics shares traded around $1.59 on 28 November, down from the previous close of $1.62 but still well above pre-October levels. No new press releases or SEC filings were issued today. The stock’s recent surge followed a major Chugai Pharmaceutical collaboration and $60.3 million private placement. Market cap stands near $190–200 million with roughly 97.5 million shares outstanding.
28 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics shares surged over 300% in a month, jumping to $2.20–$2.50 after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal brought $10 million upfront and extended Rani’s cash runway into 2028 with a $60.3 million financing. Analyst targets rose as high as $11. Trading volume spiked tenfold, with the stock breaking key technical levels.
3 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Rani Therapeutics stock surged 330% in October, closing at $2.20 on Nov. 1 after announcing a $1.085 billion licensing deal with Chugai and positive preclinical data for its oral semaglutide pill. The company, which has no approved products or meaningful revenue, raised $60.3 million in a private placement. Analysts rate RANI a Buy, but warn of high risk due to ongoing losses and no product sales.
1 November 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Rani Therapeutics shares closed at $2.20 on Oct. 31, up 51.7% for the day, following a $1.09 billion collaboration deal with Chugai Pharma and a $60.3 million equity raise. Trading volume surged, with nearly 172 million shares changing hands Oct. 20. Founder Mir Imran bought 2.08 million shares Oct. 27. Wall Street analysts now rate RANI a “Strong Buy” with average price targets near $10–11.
31 October 2025
··
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics shares jumped 248% to close at $1.64 on October 17, 2025, after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in a private placement, boosting its cash position. Rani will get $10 million upfront from Chugai and up to $175 million in milestones for its first oral drug program.
20 October 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Rani Therapeutics shares surged 248% to close at $1.64 on Oct. 17 after announcing a collaboration with Chugai Pharmaceutical worth up to $1.08 billion. The deal includes $10 million upfront and up to $175 million in milestones for the first drug. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. The company’s RaniPill technology delivers injectable drugs via oral capsules.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···

Stock Market Today

  • Roper Technologies (ROP) Trading Below Analyst Targets, Potentially Undervalued
    May 19, 2026, 11:35 PM EDT. Roper Technologies (ROP) shares fell about 9% in the past month to $328.91, with a 1-year total shareholder return down 42.68%, reflecting investor concerns over growth and risk balance. Analysts estimate a fair value around $453.75, implying the stock is 27.5% undervalued. This view hinges on Roper's continued growth via acquisitions and AI-driven software, supporting strong cash flow and EBITDA margin expansion. However, risks include potential integration challenges and rising competition. Investors are advised to carefully assess Roper's revenue trajectory, profit margins, and execution capabilities amid mixed market sentiment.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Go toTop